[The pharmacology of glisoxepide, a new oral antidiabetic].
D000818:Animals; D001381:Azepines / Q000494:pharmacology; D001646:Bile / Q000378:metabolism; D001786:Blood Glucose; D050260:Carbohydrate Metabolism; D002250:Carbon Radioisotopes; D003864:Depression, Chemical; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006003:Glycogen / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000187:drug effects; D050356:Lipid Metabolism; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D051379:Mice; D010080:Oxazoles / Q000494:pharmacology; D010973:Platelet Adhesiveness / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D013453:Sulfonylurea Compounds / Q000494:pharmacology*; D013997:Time Factors
D001381:Azepines; D001786:Blood Glucose; D002250:Carbon Radioisotopes; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D007328:Insulin; D008112:Liver Glycogen; D010080:Oxazoles; D013453:Sulfonylurea Compounds; D006003:Glycogen
Zur Pharmakologie von Glisoxepid, einem neuren oralen Antidiabetikum